Thursday, July 16, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Jul 15, 2026
Medtronic recalls catheter delivery system that may detach and cause death
background ▾
- •Class I recall of critical cardiac device component poses significant reputational and financial risk to Medtronic, with potential litigation and regulatory scrutiny given no deaths reported yet but high severity classification
- •Manufacturing defect (distal tip detachment) suggests quality control gaps in production, particularly concerning given similar adhesive/manufacturing issues in Medtronic's 2023 acid reflux device recall
- •Monitor for clinical incident reports, regulatory communications regarding root cause investigation, and potential expansion of recall scope; assess impact on Harmony TPV market adoption and physician confidence
MedtronicHarmony transcatheter pulmonary valve (TPV)Harmony delivery catheter system
→ Read original articlePolicy•KFF•Jul 16, 2026
Poll: Costs Are the Top Health Care Issue for Voters in the Midterms, But Fraud Tops Republicans’ List As Trump Administration Pushes Crackdown
background ▾
- •Trump administration's fraud crackdown messaging has effectively mobilized Republican voter concern: 55% of Republicans say fraud in government health programs is extremely important for candidates to discuss, compared to lower priority among Democrats and independents.
- •Voter consensus strongly favors access over fraud prevention: 71% of all voters say ensuring Medicaid beneficiaries can access care should be higher priority than reducing fraud, with 77% believing payment deferrals would cause eligible people to lose access.
- •Watch for escalation of federal-state conflicts over Medicaid funding and potential court challenges to payment deferral policies, as well as impact on 2024 election messaging around healthcare priorities.
Policy•STAT News•Jul 16, 2026
Opinion: Medicaid and SNAP cuts are exacerbating the intertwined problems of hunger and mental illness
background ▾
- •Medicaid and SNAP cuts totaling over $1.1 trillion over 10 years target the same vulnerable population with high rates of serious mental illness, compounding existing food insecurity-mental health crises
- •Recent causal evidence (PLOS Mental Health 2025) and meta-analysis (Journal of Psychiatric and Mental Health Nursing 2023) confirm food insecurity directly produces anxiety and depression, not merely correlates with it, making these cuts clinically consequential
- •CBO estimates 10 million people will lose Medicaid coverage; stricter SNAP work requirements (extended to age 64) and accelerated Medicaid redetermination timelines (6 months vs. annually) will likely push additional eligible patients off rolls, reducing psychiatric treatment access and increasing ED utilization
Policy•STAT News•Jul 15, 2026
Cassidy grills Trump nominee on past vaccine comments in heated exchange
background ▾
- •Kaufman, if confirmed, would oversee pandemic preparedness and response work while under Senate scrutiny for prior vaccine skepticism and opposition to mRNA vaccine research funding—a core function of his potential role
- •Cassidy has publicly stated he will not vote for any nominee who questions vaccine safety or equivocates on the topic, signaling potential confirmation risk and fracture within Trump's health team over vaccine policy
- •Watch whether Kaufman's equivocation on HHS' decision to defund mRNA vaccine research triggers additional Senate opposition or whether Cassidy's pressure influences the nominee's stated positions before a final vote
hepatitis B vaccinemRNA vaccines
→ Read original articlePolicy•KFF•Jul 15, 2026
Medicaid Postpartum Coverage Extension Tracker
background ▾
- •Medicaid postpartum coverage extension to 12 months is now permanent policy, removing the original five-year sunset and enabling indefinite state implementation
- •This policy directly addresses maternal health disparities and coverage instability affecting approximately 40% of U.S. births (Medicaid-financed), with particular impact on non-expansion states
- •Implementation varies by state approach (SPA, section 1115 waiver, or state funds); tracking adoption rates and coverage gaps will be critical to assessing public health impact and identifying remaining barriers to implementation
Market Access
Market Access•Fierce Biotech•Jul 15, 2026
Braveheart aims for freedom with IPO to support Hengrui-licensed cardio asset
background ▾
- •Braveheart's IPO represents continued investor confidence in Hengrui-derived assets and the cardiac myosin inhibitor class, following Kailera's record IPO earlier in 2025
- •BHB-1893 addresses two distinct HCM phenotypes with phase 2 efficacy signals, but faces established competitors (Camzyos, Myqorzo) and upcoming phase 3 data from Cytokinetics in nHCM
- •Global phase 3 initiation timeline (oHCM H2 2025, nHCM H1 2027) and potential regulatory pathway clarity will be critical watch points for investor conviction and competitive positioning
Braveheart BioJiangsu Hengrui PharmaceuticalsBristol Myers SquibbBHB-1893CamzyosMyqorzo
→ Read original articleMarket Access•Fierce Biotech•Jul 15, 2026
J&J MedTech growth slows again in Q2 as Abiomed weighs on results
background ▾
- •Abiomed sales contracted 2% YoY in Q2 after 14% growth in Q1, driven by lower U.S. procedure volumes amid manufacturing and safety concerns with Oscor-supplied introducer kits
- •FDA early alert in June regarding potential leakage from introducer sheaths and three reported patient deaths (though causality denied by company) have likely suppressed clinical adoption and provider confidence
- •Two failed randomized trials of miniaturized Impella pumps in coronary intervention patients represent a significant setback for pipeline expansion; monitor upcoming guidance and management commentary on market recovery timeline and potential strategic alternatives
Johnson & JohnsonAbiomedOscorImpella
→ Read original articleMarket Access•Endpoints News•Jul 15, 2026
Eli Lilly invests in Oura to support patients on GLP-1 drugs
background ▾
- •Eli Lilly is investing in digital health infrastructure (Oura wearables) to create patient support value-adds for its GLP-1 franchise
- •This reflects broader pharma strategy to embed monitoring and adherence tools alongside drugs, particularly relevant given GLP-1 side effect profiles and titration complexity
Eli LillyOuraGLP-1 agonists
→ Read original articleMarket Access•Endpoints News•Jul 15, 2026
Radiopharma maker AdvanCell hauls in $315M for Pluvicto challenger
background ▾
- •AdvanCell raised $315M Series D to develop a lead-based PSMA-targeted prostate cancer radiopharmaceutical as a direct competitor to Novartis Pluvicto
- •Funding partially allocated to expand US manufacturing infrastructure, addressing a critical supply-chain vulnerability in radiopharmaceutical production
- •Clinical and manufacturing data will be essential to assess whether AdvanCell's candidate can differentiate on efficacy, safety, or manufacturability versus Pluvicto and other PSMA-targeted competitors
AdvanCellNovartisPluvicto
→ Read original articleMarket Access•Endpoints News•Jul 15, 2026
J&J touts Icotyde prescriptions, but not sales, in first full quarter
background ▾
- •J&J released prescription data for Icotyde but deliberately omitted sales figures in Q2 earnings, an unusual communication choice that may signal slower-than-expected commercial uptake.
- •The lack of transparent revenue reporting raises questions about the drug's path to blockbuster status and suggests potential market access or uptake challenges despite regulatory approval.
- •Monitor Q3 earnings and subsequent disclosures for full sales data and competitive positioning in Icotyde's indication; assess whether J&J's prescription framing masks weaker commercial performance.
Johnson & JohnsonIcotyde
→ Read original articleClinical Trials
Clinical Trials•STAT News•Jul 16, 2026
Opinion: The growing fang-to-pharmacy pipeline
background ▾
- •Venom-derived peptides have already yielded blockbuster drugs (captopril from pit viper venom approved in 1981; ziconotide from cone snail venom)
Bristol Myers Squibbcaptoprilziconotide
→ Read original articleClinical Trials•Fierce Biotech•Jul 15, 2026
AAIC: Roche ‘very interested’ in testing tau for Alzheimer’s despite focus on phase 3-stage amyloid drug
background ▾
- •Trontinemab demonstrated sustained amyloid reduction with only 2 ARIA-E cases among 126 patients, suggesting a potentially differentiated safety/efficacy profile versus approved anti-amyloid agents
- •Roche's phase 3 Trontier trials began recruiting in September 2025 with results expected in 2028, representing the company's major near-term bet in Alzheimer's despite prior failures with gantenerumab and crenezumab
- •Watch for: phase 3 Trontier readout in 2028 and upcoming late-stage study in preclinical populations; Roche may re-enter tau space if new candidates emerge, following competitive tau data from Biogen's diranersen
RocheBiogenEli LillytrontinemabdiranersenLeqembi
→ Read original articleClinical Trials•Fierce Biotech•Jul 15, 2026
Big Pharma-backed AdvanCell, flush with $315M series D, ready to put radiotherapy pedal to the metal
background ▾
- •AdvanCell's ADVC001 targets a significant unmet need: ~30% of Pluvicto patients are upfront resistant, and lead-212's double-strand DNA breaks may offer a resistance-resistant mechanism versus lutetium-based competitors
- •The $315M raise signals strong institutional confidence in radiotherapy resurgence and AdvanCell's platform, with participation from Sanofi, Eli Lilly, Ally Bridge, Alpha Wave, and Bain Capital
- •Manufacturing scale-up and phase 3 initiation timeline are critical near-term milestones to watch; lead-212's shorter half-life and automated production could prove decisive competitive advantages if clinical efficacy/safety profile validates the mechanism
AdvanCellSanofiEli LillyADVC001lead-212Pluvicto
→ Read original articleClinical Trials•Fierce Biotech•Jul 15, 2026
J&J axes eye disease gene therapy after key phase 2b readout
background ▾
- •Phase 2b Parasol trial of JNJ-1887 failed to meet efficacy expectations, leading J&J to exit a gene therapy program it acquired from Hemera Biosciences in 2020
- •The failure underscores the challenges in translating complement-pathway inhibition into clinical benefit for geographic atrophy, despite sound mechanistic rationale (CD59 inhibits membrane attack complex)
- •Competitive landscape remains active: Sanofi's SAR446597 (dual C1s/factor Bb inhibitor) entered Phase 2 in 2024 and may provide early signals on alternative complement-targeting strategies in geographic atrophy
Johnson & JohnsonHemera BiosciencesSanofiJNJ-1887HMR59SAR446597
→ Read original articleClinical Trials•Endpoints News•Jul 15, 2026
Veradermics declares first efficacy win in women for hair loss drug
background ▾
- •Veradermics' oral minoxidil shows efficacy in female pattern hair loss—a new indication not previously established for this formulation and significantly broadening market potential
- •This efficacy win in women de-risks the commercial strategy and may accelerate regulatory discussions; however, comparative efficacy versus topical minoxidil and phase progression timeline are unknown
- •Watch for full trial readout details, regulatory feedback on female-focused development pathway, and competitive positioning against other oral hair loss therapies in development
Veradermicsminoxidil (oral)
→ Read original article